CMGE Technology Group Limited announced three separate share subscription agreements after market close on 20 April 2026, securing total gross proceeds of HK$30.00 million.
Key transaction terms • Shares issued: 122.95 million new shares, equal to 4.10% of CMGE’s 2.99 billion issued shares and 3.93% of the enlarged 3.12 billion share base post-completion. • Subscription price: HK$0.244 per share, reflecting a 6.15% discount to the 20 April closing price (HK$0.260) and a 2.40% discount to the five-day average (HK$0.250). • Net proceeds: approximately HK$29.50 million after ~HK$0.50 million in expenses; the funds are earmarked for game-publishing costs. • Completion: within five business days after contract execution, subject to customary conditions including Stock Exchange approval for listing the new shares.
Subscribers 1. Secure Precision Limited (40.98 million shares), ultimately owned by Madam Yang Mei. 2. Tanwan Inc. (40.98 million shares), a Hong Kong-listed game company (stock code 09890) focusing on “AI + Gaming”. 3. Shengqu Technology Korean Limited (40.98 million shares), wholly owned by Shenzhen-listed Zhejiang Century Huatong Group Co., Ltd. (002602.SZ).
Mandate and dilution The placement utilises the company’s existing general mandate, which permits issuance of up to 599.08 million shares; no prior issuances have been made under this authority. Post-transaction, total outstanding shares will increase to 3.12 billion, diluting existing holdings by 3.93%.
Revised shareholding snapshot • Public shareholders: from 47.36% to 45.49%. • Fairview Ridge Investment Limited (largest shareholder): from 23.14% to 22.23%. • New investors (combined): 3.10% of enlarged capital.
Contingencies and termination If listing approval is not obtained within 28 days after payment, CMGE must refund the consideration with 4.6% annual interest; a 10% rate applies on overdue refunds. Each agreement may be terminated independently if payment is not made in full.
CMGE has conducted no other equity fundraising in the past 12 months. Shareholders are reminded that completion remains conditional on regulatory approvals.
Comments